WO2004062623A3 - Method of treating functional bowel disorders - Google Patents

Method of treating functional bowel disorders Download PDF

Info

Publication number
WO2004062623A3
WO2004062623A3 PCT/US2004/000807 US2004000807W WO2004062623A3 WO 2004062623 A3 WO2004062623 A3 WO 2004062623A3 US 2004000807 W US2004000807 W US 2004000807W WO 2004062623 A3 WO2004062623 A3 WO 2004062623A3
Authority
WO
WIPO (PCT)
Prior art keywords
functional
subject
functional bowel
bowel disorders
nari
Prior art date
Application number
PCT/US2004/000807
Other languages
French (fr)
Other versions
WO2004062623A2 (en
Inventor
Steven B Landau
Original Assignee
Dynogen Pharmaceuticals Inc
Steven B Landau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc, Steven B Landau filed Critical Dynogen Pharmaceuticals Inc
Priority to NZ541008A priority Critical patent/NZ541008A/en
Priority to MXPA05007381A priority patent/MXPA05007381A/en
Priority to BR0406749-5A priority patent/BRPI0406749A/en
Priority to AU2004204825A priority patent/AU2004204825B2/en
Priority to JP2006500936A priority patent/JP2006516976A/en
Priority to CA002512983A priority patent/CA2512983A1/en
Priority to EP04701811A priority patent/EP1558081A4/en
Publication of WO2004062623A2 publication Critical patent/WO2004062623A2/en
Publication of WO2004062623A3 publication Critical patent/WO2004062623A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.
PCT/US2004/000807 2003-01-13 2004-01-13 Method of treating functional bowel disorders WO2004062623A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NZ541008A NZ541008A (en) 2003-01-13 2004-01-13 Method of treating functional bowel disorders
MXPA05007381A MXPA05007381A (en) 2003-01-13 2004-01-13 Method of treating functional bowel disorders.
BR0406749-5A BRPI0406749A (en) 2003-01-13 2004-01-13 Methods related to treatment of bowel dysfunction and pharmaceutical composition
AU2004204825A AU2004204825B2 (en) 2003-01-13 2004-01-13 Method of treating functional bowel disorders
JP2006500936A JP2006516976A (en) 2003-01-13 2004-01-13 How to treat functional bowel disorders
CA002512983A CA2512983A1 (en) 2003-01-13 2004-01-13 Method of treating functional bowel disorders
EP04701811A EP1558081A4 (en) 2003-01-13 2004-01-13 Method of treating functional bowel disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44007703P 2003-01-13 2003-01-13
US60/440,077 2003-01-13
US49248003P 2003-08-04 2003-08-04
US60/492,480 2003-08-04

Publications (2)

Publication Number Publication Date
WO2004062623A2 WO2004062623A2 (en) 2004-07-29
WO2004062623A3 true WO2004062623A3 (en) 2005-06-09

Family

ID=32718145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000807 WO2004062623A2 (en) 2003-01-13 2004-01-13 Method of treating functional bowel disorders

Country Status (13)

Country Link
US (8) US20040147509A1 (en)
EP (2) EP1558081A4 (en)
JP (2) JP2006516976A (en)
KR (1) KR20050111318A (en)
CN (1) CN100353946C (en)
AU (1) AU2004204825B2 (en)
BR (1) BRPI0406749A (en)
CA (1) CA2512983A1 (en)
MX (1) MXPA05007381A (en)
NZ (1) NZ541008A (en)
PL (1) PL378367A1 (en)
WO (1) WO2004062623A2 (en)
ZA (1) ZA200505817B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
DE602004005814T2 (en) * 2003-01-13 2008-01-10 Dynogen Pharmaceuticals Inc., Waltham PROCEDURE FOR TREATING EVILNESS, INFRINGEMENT, ORGANIZATION OR ANY COMBINATION THEREOF
EP1539181B1 (en) * 2003-04-04 2007-06-27 Dynogen Pharmaceuticals Inc. Method of treating lower urinary tract disorders
JP4725579B2 (en) * 2005-01-28 2011-07-13 アステラス製薬株式会社 Screening method for drugs for irritable bowel syndrome
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
EP1942894A4 (en) * 2005-10-07 2011-02-09 Colocaps Pty Ltd Preparation for the treatment of diarrhoea
KR101300493B1 (en) * 2005-12-02 2013-09-02 아이로보트 코퍼레이션 Coverage robot mobility
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120445A1 (en) * 2006-03-31 2007-10-25 Dynogen Pharmaceuticals, Inc. SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES
TW200838534A (en) * 2007-02-07 2008-10-01 Astellas Pharma Inc Treatment for irritable bowel syndrome
WO2010024306A1 (en) * 2008-08-28 2010-03-04 アステラス製薬株式会社 Method for treating irritable bowel syndrome
HUE030811T2 (en) * 2011-10-18 2017-05-29 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
JOP20130213B1 (en) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co 5-ht3 receptor antagonists
BR112015015258A2 (en) 2012-12-24 2017-09-26 Neurogastrx Inc Methods to Treat Gastrointestinal Tract Disorders
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
PT3201203T (en) 2014-09-29 2021-08-09 Takeda Pharmaceuticals Co Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US20240003872A1 (en) * 2020-11-15 2024-01-04 Aphios Corporation Methods for assaying and measuring the efficacy of anti-nausea compounds
CN113412817B (en) * 2021-05-31 2022-07-12 成都中医药大学附属医院 IBS-D experimental animal model method for improving molding rate and reducing death rate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039599A1 (en) * 1995-05-17 2002-04-04 Lin Henry C. Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6475078B1 (en) * 2001-10-09 2002-11-05 Norb Borcherding Air ventilating device

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US659336A (en) * 1900-05-25 1900-10-09 Charles H Booth Pipe-coupling.
JPS60146891A (en) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd (2,3-d)thienopyrimidine derivative and its salt
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
EP0297651B1 (en) * 1987-06-29 1993-11-03 Duphar International Research B.V Anellated indole derivatives
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
EP1022025A3 (en) * 1991-06-26 2002-06-05 Sepracor, Inc. Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron
JP2699794B2 (en) * 1992-03-12 1998-01-19 三菱化学株式会社 Thieno [3,2-b] pyridine derivative
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
DE4238553A1 (en) * 1992-11-14 1994-05-19 Kali Chemie Pharma Gmbh New drugs containing imidazol-1-yl compounds
JPH0616557A (en) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp Improver for cerebral cerebral function disorder
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
JPH11505258A (en) * 1995-05-17 1999-05-18 セダーシナイ メディカル センター Compositions comprising fatty acids that improve digestion and absorption in the small intestine
CN1096459C (en) * 1995-07-28 2002-12-18 大日本制药株式会社 (R)-5-bromo-N-(1-ethyl-4-methylhexahy dro-1H-1,4-diazepin-6-YL)-2-methoxy-6-methylamino-3-pyridine-carboxamide
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
WO1997029739A2 (en) * 1996-02-15 1997-08-21 Janssen Pharmaceutica N.V. Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9701304D0 (en) * 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
WO1998047481A1 (en) * 1997-04-18 1998-10-29 Janssen Pharmaceutica N.V. Use of 5ht3 antagonists for promoting intestinal lavage
US6177879B1 (en) * 1997-05-09 2001-01-23 Honda Giken Kogyo Kabushiki Kaisha Battery rental system and apparatus
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
JP4083818B2 (en) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド Gastric retentive oral drug dosage form for controlled release of highly soluble drugs
DE19813661A1 (en) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Pharmaceutical preparations from Cilansetron stabilized against racemization
DE19734444A1 (en) * 1997-08-08 1999-02-11 Basf Ag 3-Substituted 3,4,5,7-tetrahydro-pyrrolo (3 ', 4': 4,5) thieno (2,3-d) pyrimidine derivatives, their preparation and use
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
US6054461A (en) * 1997-09-16 2000-04-25 Solvay Pharmaceuticals Gmbh Treatment of neuropathic pain
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6456458B1 (en) * 1998-08-08 2002-09-24 Nidec Corporation Disk-drive motor rotating on a magnetically counterbalanced single hydrodynamic thrust bearing
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
ATE434437T1 (en) * 1999-02-18 2009-07-15 Novasearch Ag USE OF ANTAGONISTS OF 5-HT3 RECEPTORS FOR THE TREATMENT OF MUSCULOESKELETAL DISEASES
AU2672500A (en) * 1999-02-18 2000-09-04 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19911371A1 (en) * 1999-03-15 2000-09-21 Solvay Pharm Gmbh Medicines for the treatment of functional disorders and diseases of the lower intestinal tract, in particular associated abdominal visceral pain
US6448962B1 (en) 1999-05-14 2002-09-10 Three-Five Systems, Inc. Safety timer to protect a display from fault conditions
DE19929197A1 (en) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermal systems for the delivery of 5-HT3 receptor antagonists and their use for antiemitic treatment
DE60020613T2 (en) * 1999-07-01 2006-03-16 Pharmacia & Upjohn Co. Llc, Kalamazoo (S, S) reboxetine for the treatment of fibromyalgia and other somatoform disorders
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
MXPA02004413A (en) 1999-11-02 2002-09-02 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach.
ATE340563T1 (en) 2000-02-04 2006-10-15 Depomed Inc SHELL AND CORE TYPE DOSAGE FORM WITH A RELEASE OF ACTIVE INGREDIENTS APPROACHING TO THE ZERO ORDER
JP2001243182A (en) 2000-02-29 2001-09-07 Nec Corp Server system, and method for interlocking web contents with the server system
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6566369B2 (en) * 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US6588708B2 (en) * 2001-01-29 2003-07-08 The Boeing Company Spacecraft methods and structures for acquiring and determining power-safe attitudes
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
GB0112494D0 (en) * 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
KR20040020056A (en) 2001-05-29 2004-03-06 디포메드 디벨롭먼트 리미티드 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US6568519B2 (en) 2001-08-10 2003-05-27 Borgwarner, Inc. Torque limiting chain sprocket assembly
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
WO2003035039A1 (en) 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US6458795B1 (en) * 2001-11-15 2002-10-01 University Of Florida Method and composition for treatment of irritable bowel disease
WO2003061657A1 (en) * 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
JP2005526079A (en) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド NE and 5-HT reuptake inhibitors for treating visceral pain syndrome
US20040032780A1 (en) * 2002-04-08 2004-02-19 Ehud Langberg System and method for generating a clock signal in a communication system
EP1519728B1 (en) * 2002-07-10 2009-03-11 Dynogen Pharmaceuticals, Inc. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
WO2004019948A1 (en) * 2002-08-29 2004-03-11 Arachnova Therapeutics Ltd. New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2­-(1-piperazinyl) thieno[2,3-d]pyrimidine
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
DE602004005814T2 (en) * 2003-01-13 2008-01-10 Dynogen Pharmaceuticals Inc., Waltham PROCEDURE FOR TREATING EVILNESS, INFRINGEMENT, ORGANIZATION OR ANY COMBINATION THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039599A1 (en) * 1995-05-17 2002-04-04 Lin Henry C. Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6475078B1 (en) * 2001-10-09 2002-11-05 Norb Borcherding Air ventilating device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"How to avoid a health insurance claim denial- and what to when you can't", INSURE.COM, 3 January 2002 (2002-01-03), pages 4, XP002986530, Retrieved from the Internet <URL:http://info.insure.com/health/claimdenial.html> *
EGUCHI ET AL.: "The anxiolytic-like effect of MCI-225, a selective NA renptake inhibitor with 5-HT3 receptor antagonism", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 68, 2001, pages 677 - 683, XP002239887 *
See also references of EP1558081A4 *

Also Published As

Publication number Publication date
EP2286817A2 (en) 2011-02-23
JP2006516976A (en) 2006-07-13
CA2512983A1 (en) 2004-07-29
AU2004204825A1 (en) 2004-07-29
KR20050111318A (en) 2005-11-24
US20040254170A1 (en) 2004-12-16
EP2286817A3 (en) 2011-06-15
JP2011157372A (en) 2011-08-18
NZ541008A (en) 2007-09-28
EP1558081A2 (en) 2005-08-03
US20060217391A1 (en) 2006-09-28
CN1750759A (en) 2006-03-22
US20040259862A1 (en) 2004-12-23
MXPA05007381A (en) 2006-02-10
US20040254169A1 (en) 2004-12-16
PL378367A1 (en) 2006-04-03
US20050032780A1 (en) 2005-02-10
CN100353946C (en) 2007-12-12
US20050192270A1 (en) 2005-09-01
US20040147509A1 (en) 2004-07-29
US20040254168A1 (en) 2004-12-16
BRPI0406749A (en) 2005-12-20
ZA200505817B (en) 2006-04-26
EP1558081A4 (en) 2006-06-14
AU2004204825B2 (en) 2007-07-19
WO2004062623A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
WO2004062623A3 (en) Method of treating functional bowel disorders
WO2004089288A3 (en) Method of treating lower urinary tract disorders
WO2004062624A3 (en) Method of treating nausea, vomiting, retching or any combination thereof
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2005079795A3 (en) Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
WO2006042150A8 (en) Diaminoalkane aspartic protease inhibitors
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
TNSN07312A1 (en) Combination of organic compounds
TW200633980A (en) Pyridones useful as inhibitors of kinases
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2004103288A3 (en) Method of preventing recurrent miscarriages
WO2006009975A3 (en) Histamine to treat disorders affecting muscle function
WO2007011702A3 (en) Use of egfr inhibitors to prevent or treat obesity
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2006133374A3 (en) Methods for treating shock
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
WO2003057140A3 (en) Composition and methods for treatment of neurological disorders
WO2006053014A3 (en) Selective inhibition of rock1 in cardiac therapy
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
WO2006044582A3 (en) Use of baff to treat sepsis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2004204825

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2004204825

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004701811

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 169413

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 541008

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2967/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/007381

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006500936

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2512983

Country of ref document: CA

Ref document number: 1020057012930

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 378367

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2005/05817

Country of ref document: ZA

Ref document number: 200505817

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2004701811

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20048042278

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057012930

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0406749

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2004204825

Country of ref document: AU